Diffuse Astrocytoma Clinical Trials

7 recruitingLast updated: June 18, 2026

There are 7 actively recruiting diffuse astrocytoma clinical trials across 20 countries. Studies span Phase 1, Not Applicable, Phase 2, Phase 4. Top locations include New York, New York, United States, Memphis, Tennessee, United States, Houston, Texas, United States. Updated daily from ClinicalTrials.gov.


Diffuse Astrocytoma Trials at a Glance

7 actively recruiting trials for diffuse astrocytoma are listed on ClinicalTrialsFinder across 6 cities in 20 countries. The largest study group is Phase 1 with 3 trials, with the heaviest enrollment activity in New York, Memphis, and Houston. Lead sponsors running diffuse astrocytoma studies include M.D. Anderson Cancer Center, Memorial Sloan Kettering Cancer Center, and Jazz Pharmaceuticals.

Browse diffuse astrocytoma trials by phase

Treatments under study

About Diffuse Astrocytoma Clinical Trials

Looking for clinical trials for Diffuse Astrocytoma? There are currently 3 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Diffuse Astrocytoma trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Diffuse Astrocytoma clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 17 of 7 trials

Recruiting
Not Applicable

Evaluation of Hippocampal-Avoidance Using Proton Therapy in Low-Grade Glioma

Optic pathway gliomaGliomaPilocytic Astrocytoma+4 more
St. Jude Children's Research Hospital74 enrolled2 locationsNCT04065776
Recruiting
Phase 4

Pediatric Long-Term Follow-up and Rollover Study

Neurofibromatosis Type 1GlioblastomaAnaplastic Astrocytoma+20 more
Novartis Pharmaceuticals165 enrolled55 locationsNCT03975829
Recruiting
Phase 1

A Study of 177Lu-PSMA-617 in People With Gliomas

GliomaGlioblastoma, IDH-wildtypeDiffuse Midline Glioma, H3 K27-Altered+3 more
Memorial Sloan Kettering Cancer Center20 enrolled7 locationsNCT07223034
Recruiting
Not Applicable

PRO-GLIO: PROton Versus Photon Therapy in IDH-mutated Diffuse Grade II and III GLIOmas

Diffuse Astrocytoma, IDH-MutantOligodendrogliomaOligodendroglioma, Anaplastic
Oslo University Hospital225 enrolled1 locationNCT05190172
Recruiting
Phase 1Phase 2

Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis

Colorectal, CancerEsophageal CancerGastric Cancer+18 more
Neonc Technologies, Inc.134 enrolled6 locationsNCT06047379
Recruiting
Phase 2

Chemotherapy and Radiation Therapy for the Treatment of IDH Wildtype Gliomas or Non-histological (Molecular) Glioblastomas

GlioblastomaOligodendrogliomaWHO Grade III Glioma+6 more
M.D. Anderson Cancer Center40 enrolled1 locationNCT04623931
Recruiting
Phase 1

Phase I Study of Oral ONC206 in Recurrent and Rare Primary Central Nervous System Neoplasms

Central Nervous System NeoplasmsGlioblastomaOligodendroglioma+20 more
Jazz Pharmaceuticals102 enrolled1 locationNCT04541082